Advancing technology and a unique wealth of knowledge are the driving forces behind innovative development in our PathFlow® portfolio of diagnostic tests for infectious diseases.
Our latest addition to the range – the PathFlow® SARS-CoV-2 IgG – is an easy-to-use, rapid, lateral flow test for the detection of COVID-19 antibodies.
It’s a natural evolution in the Novacyt Group’s range of COVID-19 diagnostic solutions, building on our growing expertise in this field, plus our ability to maximise the potential of our technologies and science.
The PathFlow® SARS-CoV-2 IgG rapid test cassette offers a fast turnaround time, with results in as little as 10 minutes – which in some cases is half the time of other products on the marketplace.
The design of PathFlow® assays capitalises on the utilisation of colloidal gold particles as detector reagents. This delivers a high performing and reliable method for detecting antibodies to the ‘S’ protein receptor binding domain (RBD) and in the ‘N’ proteins of SARS-CoV-2 in human whole blood, plasma or serum.
The new test not only identifies people who have built up antibodies in response to being infected with SARS-CoV-2, but can also be used to assess an individual’s response to immunisation. Understanding if someone has developed an immune response to SARS-CoV-2 as a result of either infection or vaccination is a pivotal step forward, not only in our understanding of the virus but also in our ability to combat it.
We’ve developed the PathFlow® SARS-CoV-2 rapid test to be used for sero-surveillance and assessing vaccine efficacy. Potential applications include academia and research, immunity passports and for corporate use in assessing employee immunity.
The new test builds on the past 18 months of our Novacyt product development and innovation in developing assays to help assess and manage the COVID-19 pandemic.
This includes innovative product development in our PathFlow® portfolio – part of our Microgen Bioproducts division – where the new SARS-CoV-2 IgG rapid test is a natural addition to a fast-growing range of assays for the rapid diagnosis of infectious diseases.
With more than 20 years’ experience in the food industry, helping food manufacturers ensure consumer safety, our PathFlow® research and development team has an established track record. We have since utilised our growing expertise and knowledge base to create a broad range of high-quality diagnostic products for clinical use. Offering accurate, rapid & cost-effective detection methods for many common bacterial & viral infections – alongside key toxins and biomarkers.
As part of the Novacyt Group, Microgen Bioproducts and the PathFlow® portfolio benefit from synergies with other group divisions, sharing knowledge, expertise and experience across a rapidly growing, international diagnostics organisation, which specialises in diagnostic and pathogen testing kits based on molecular and protein testing technologies for the human clinical, life science, food and industrial markets.
With a global distribution network, monitoring customer feedback is an integral part of our R&D schedule, where product enhancements and new ideas for development ensure we continue to meet unmet need. This also helps to maintain our competitive edge with differentiated assays in a dynamic marketplace for rapid testing.
We are also building our partnerships with academia, to help further clinical studies as we evolve the new product development programme.
Our aim is to meet unmet patient needs – to plug any gaps in the detection of infectious diseases – and to create innovative solutions that are stand-out pacesetters in the marketplace.
“PathFlow® and the Microgen Products R&D team benefit from the unrivalled expertise and knowledge base within the Novacyt Group. Our shared purpose is to be a world-leading innovator in diagnostic testing, and we are all equally passionate about identifying patient need and overcoming significant healthcare challenges today and in the years ahead.” Product Manager, Novacyt Group.
PathFlow® is committed to continuous product innovation that develops high performing rapid testing products that enable actionable results for better patient management and care – and ultimately better patient outcomes.